Fully human antibody is at the preclinical stage of development.
DSM Biologics and MorphoSys signed an agreement covering process development and cGMP manufacturing of MOR202. This fully human HuCAL® antibody is directed against CD38, a target for the treatment of multiple myeloma.
DSM Biologics will produce MOR202 in its cGMP facilities in Groningen, the Netherlands.
